Patient advocacy and access to innovative clinical trials in a changed environment (COVID 19)
1:29:30
Description
Related Videos
View More
View Less
1:29:30
With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.
1:02:03
32:11
With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.
1:02:03
In this webinar, medical ethicists will discuss what investigators, ethics committees, IRBs and – ideally – sponsors can do to reverse this trend and create documents which achieve their intended purpose of allowing a child to understand their trial.
1:02:52
With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.
1:02:03
1:01:11